Chaiyasit Noppadol, Taneepanichskul Surasak
Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
J Med Assoc Thai. 2010 May;93(5):517-22.
To study cycle control, side effects, and satisfaction of low dose 24-day combined contraceptive containing 20 microg of Ethinylestradiol and 3 mg of Drospirenone.
This was an open label, non-comparative study. The healthy females from the family planning clinic at King Chulalongkorn Memorial Hospital were assigned to receive six cycles of combined oral contraceptive containing 20 microg of ethinylestradiol and 3 mg of drospirenone administered daily for 24 days followed by 4-day hormone-free interval. Data were collected on cycle control, side effects, and satisfaction. Data were analyzed using descriptive statistics for descriptive data and Paired t test for comparison.
One hundred fifty four women were assigned the study medication, including one (0.64%) who did not start medication. In the second reference period, the occurrence of frequent and infrequent bleeding was low (2.1% and 4.9%). Only one woman (0.65%) discontinued medication because of irregular bleeding. There was no pregnancy reported during the present study. Overall, the study medication was well tolerated and five subjects (3.24%) discontinued study because of side effects. No serious side effects related to the study medication were reported. The majority of women (84.2%) were satisfied and very satisfied with the treatment and most (73.3%) would continue the medication if it were available.
The low dose combined contraceptive containing Ethinylestradiol/Drospirenone (24/4 regimen) has acceptable cycle control and good tolerability.
研究含20微克炔雌醇和3毫克屈螺酮的低剂量24天复方避孕药的周期控制、副作用及满意度。
这是一项开放标签、非对照研究。来自朱拉隆功国王纪念医院计划生育门诊的健康女性被分配接受六个周期的复方口服避孕药，其中含20微克炔雌醇和3毫克屈螺酮，每日服用24天，随后为4天的无激素间隔期。收集有关周期控制、副作用和满意度的数据。使用描述性统计分析描述性数据，使用配对t检验进行比较。
154名女性被分配接受研究药物治疗，其中1名（0.64%）未开始用药。在第二个参考期，频繁出血和偶尔出血的发生率较低（分别为2.1%和4.9%）。只有1名女性（0.65%）因不规则出血而停药。本研究期间未报告怀孕情况。总体而言，研究药物耐受性良好，5名受试者（3.24%）因副作用而停止研究。未报告与研究药物相关的严重副作用。大多数女性（84.2%）对治疗感到满意或非常满意，大多数（73.3%）表示如果有这种药物，她们会继续服用。
含炔雌醇/屈螺酮的低剂量复方避孕药（24/4方案）具有可接受的周期控制和良好的耐受性。
